Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia
NCT ID: NCT02020109
Last Updated: 2018-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2013-09-30
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
NCT07030400
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
NCT07014917
An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.
NCT02528838
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
NCT00267059
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
NCT00751296
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Chronic Lymphatic Leukemia
Patients with Chronic Lymphatic Leukemia treated with splenic irradiation
splenic irradiation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
splenic irradiation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht Radiation Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jacques Borger, dr.
Role: PRINCIPAL_INVESTIGATOR
Maastro Clinic, The Netherlands
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maastro Clinic
Maastricht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-11-05/06-extern-6295
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.